ALDEYRA THERAPEUTICS, INC. (ALDX) Files An 8-K Results of Operations and Financial Condition

Item2.02.

On November14, 2016, Aldeyra Therapeutics, Inc. (Aldeyra) issued
a press release and is holding a conference call regarding its
financial results for the quarter ended September30, 2016. The
press release is furnished as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated by reference herein.

Various statements to be made during the conference call are
forward-looking statements under the securities laws, including,
but not limited to, statements regarding Aldeyras plans for its
product candidates. In some cases, you can identify forward
looking statements by terms such as, but not limited to, may,
might, will, objective, intend, should, could, can, would,
expect, believe, anticipate, project, target, design, estimate,
predict, potential, plan or the negative of these terms, and
similar expressions intended to identify forward-looking
statements. Such forward- looking statements are based upon
current expectations that involve risks, changes in
circumstances, assumptions and uncertainties.

Aldeyra is at an early stage of development and may not ever have
any products that generate significant revenue. Important factors
that could cause actual results to differ materially from those
reflected in Aldeyras forward-looking statements include, among
others, the timing of enrollment, commencement and completion of
Aldeyras clinical trials, the timing and success of preclinical
studies and clinical trials conducted by Aldeyra and its
development partners; the ability to obtain and maintain
regulatory approval to conduct clinical trials and to
commercialize Aldeyras product candidates, and the labeling for
any approved products; the scope, progress, expansion, and costs
of developing and commercializing Aldeyras product candidates;
the size and growth of the potential markets for Aldeyras product
candidates and the ability to serve those markets; Aldeyras
expectations regarding Aldeyras expenses and revenue, the
sufficiency of Aldeyras cash resources and needs for additional
financing; the rate and degree of market acceptance of any of
Aldeyras product candidates; Aldeyras expectations regarding
competition; Aldeyras anticipated growth strategies; Aldeyras
ability to attract or retain key personnel; the anticipated
trends and challenges in Aldeyras business and the market in
which it operates; and other factors that are described in the
Risk Factors and Managements Discussion and Analysis of Financial
Condition and Results of Operations sections of Aldeyras Annual
Report on Form 10-K for the year ended December31, 2015 and
Aldeyras Quarterly Report on Form 10-Q for the quarter ended
June30, 2016, which are on file with the Securities and Exchange
Commission (SEC) and available on the SECs website at
www.sec.gov. Additional information will also be set forth in
those sections of Aldeyras Quarterly Report on Form 10-Q for the
quarter ended September30, 2016, which will be filed with the SEC
in the fourth quarter of 2016.

In addition to the risks described above and in Aldeyras other
filings with the SEC, other unknown or unpredictable factors also
could affect Aldeyras results. No forward-looking statements can
be guaranteed and actual results may differ materially from such
statements.The information conveyed on the conference call is
provided only as of the date of the call, and Aldeyra undertakes
no obligation to update any forward-looking statements presented
on the call on account of new information, future events, or
otherwise, except as required by law.

The information in Item2.02 of this Current Report on Form 8-K
and the Exhibit attached hereto shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended (the Securities Act), or the Exchange Act, except as
expressly set forth by specific reference in such a filing.

(d)Exhibits

About ALDEYRA THERAPEUTICS, INC. (ALDX)